Mozart Therapeutics
Mozart Therapeutics develops therapies for celiac disease and other immune-related conditions.
Facts
- HQ
- Seattle, Washington, USA
- Sectors
- Biotechnology, Biopharma, Immunology
- Founded
- 2023
- Type
- Corporation Seattle business license
- Registered name
- Mozart Therapeutics Inc Seattle business license
- Stage
- Series C
Is this your organization? Claim it
Ally.io raises $50M Series C, bringing total funding to $76M; investors include Accel, Addition, GreenOaks
Ally.io, a Seattle-based company led by co-founder & CEO Vetri Vellore, has raised $76M total with a $50M Series C as its most recent round in February 2021, backed by investors including Accel, Addition, and GreenOaks.
Mozart Therapeutics Raises $25M to Advance Autoimmune Disease Drug MTX-101 with FDA IND Planned for Early 2024
Seattle biotech Mozart Therapeutics secured $25 million to advance MTX-101, its drug candidate for autoimmune gastrointestinal diseases, aiming for FDA IND submission by early 2024. The company, led by CEO Katie Fanning and supported by notable investors, has raised a total of $80 million since its 2020 launch.
Mozart Therapeutics Raises $55M to Advance Preclinical Celiac and Autoimmune Therapies
Mozart Therapeutics, a Seattle biotech founded last year, raised $55 million to advance preclinical development of its lead compound targeting celiac disease and other autoimmune or inflammatory conditions.
People
-
Katie Fanning Executive, President and Chief Executive Officer
Questions about Mozart Therapeutics
What is Mozart Therapeutics?
Mozart Therapeutics is a startup that develops therapies for celiac disease and other immune-related conditions, based in Seattle, Washington, USA.
What is Mozart Therapeutics known for?
GeekWire reported in June 2023 that Mozart Therapeutics was advancing the autoimmune disease drug MTX-101, with an FDA IND planned for early 2024.
What has Mozart Therapeutics been in the news for?
GeekWire reported in June 2023 that Mozart Therapeutics was advancing the autoimmune disease drug MTX-101, with an FDA IND planned for early 2024.
Who are the people behind Mozart Therapeutics?
Katie Fanning is president and chief executive officer of Mozart Therapeutics.
Who invested in Mozart Therapeutics, and how much has it raised?
Members of Seattle Flow see Mozart Therapeutics' funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Mozart Therapeutics based?
Mozart Therapeutics is based in Seattle, Washington, USA.